{"transactions":[{"id":685090,"issuer":{"id":7139,"kind":"organization","name":"ImageneBio, Inc."},"owners":[{"id":22754,"kind":"person","name":"Yarema Kristin","position":1,"cik":"0001803794","reported_name":"Yarema Kristin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2026-08-17T21:00:13.000Z","date":"2026-08-14","kind":"grant","planned":false,"acquired":true,"shares":250000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The options vest over four years in a series of 48 successive equal monthly installments commencing on May 14, 2026, subject to the Reporting Person's continuous service with the Issuer through each such vesting date."}],"balance_after":250000,"derivative":{"exercise_price":5.84,"expiration_date":"2036-08-13","underlying":"Common Stock","underlying_shares":250000},"source":{"system":"sec-edgar","filing":"0001803794-26-000003","document":"form4-08172026_050803.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1803794/000180379426000003/form4-08172026_050803.xml","form_type":"4"}},{"id":685089,"issuer":{"id":7139,"kind":"organization","name":"ImageneBio, Inc."},"owners":[{"id":22754,"kind":"person","name":"Yarema Kristin","position":1,"cik":"0001803794","reported_name":"Yarema Kristin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-08-17T21:00:13.000Z","date":"2026-08-14","kind":"grant","planned":false,"acquired":true,"shares":137200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vest over four years, with 25% of the shares vesting on April 14, 2027, and the remaining shares vesting in a series of 36 successive equal monthly installments thereafter, subject to the Reporting Person's continuous service with the Issuer through each such vesting date."}],"balance_after":137200,"derivative":{"exercise_price":5.84,"expiration_date":"2036-08-13","underlying":"Common Stock","underlying_shares":137200},"source":{"system":"sec-edgar","filing":"0001803794-26-000003","document":"form4-08172026_050803.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1803794/000180379426000003/form4-08172026_050803.xml","form_type":"4"}},{"id":685088,"issuer":{"id":7139,"kind":"organization","name":"ImageneBio, Inc."},"owners":[{"id":22754,"kind":"person","name":"Yarema Kristin","position":1,"cik":"0001803794","reported_name":"Yarema Kristin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-08-17T21:00:13.000Z","date":"2026-08-14","kind":"grant","planned":false,"acquired":true,"shares":254800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares of the Issuer's Common Stock underlying restricted stock units (\"RSUs\"). Each RSU represents the contingent right to receive one share of Common Stock upon settlement. 25% of RSUs will vest and settle into Common Stock on April 14, 2027, and the remaing RSUs will vest in a series of 12 equal quarterly installments thereafter, subject to the Reporting Person's continuous service with the Issuer through each such vesting date."}],"balance_after":493705,"source":{"system":"sec-edgar","filing":"0001803794-26-000003","document":"form4-08172026_050803.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1803794/000180379426000003/form4-08172026_050803.xml","form_type":"4"}},{"id":702025,"issuer":{"id":7139,"kind":"organization","name":"ImageneBio, Inc."},"owners":[{"id":22754,"kind":"person","name":"Yarema Kristin","position":1,"cik":"0001803794","reported_name":"Yarema Kristin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Restricted Stock Units","published_at":"2026-07-28T20:05:06.000Z","date":"2026-07-25","kind":"other","planned":false,"acquired":false,"shares":115129,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each RSU represents a contingent right to receive one share of the Issuer's common stock."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On July 28, 2025, the Reporting Person was granted restricted stock units (\"RSUs\"), which RSUs were previously reported in Table II. Effective with this filing, the Reporting Person has elected to report grants of RSUs that are settleable solely in shares of the Issuer's common stock in Table I as acquisitions of common stock, rather than in Table II as derivative securities. Previously reported unvested RSUs that had been reported in Table II are included in the amount of securities beneficially owned shown in Column 5 of Table I. The 115,129 unvested RSUs carried over from prior Table II reporting represent grant awarded on July 28, 2025 that vests on the schedule described in footnote 3. As reported in Column 9 of Table II, there are no remaining RSUs that settle in common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSUs vest over four years, with 25% of the shares subject to RSUs vesting on the one-year anniversary of the vesting commencement date and the remaining 75% of the shares vesting in equal quarterly installments over the following 12 quarterly dates."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The RSUs vest over four years, with 25% of the shares subject to RSUs vesting on the one-year anniversary of the vesting commencement date and the remaining 75% of the shares vesting in equal quarterly installments over the following 12 quarterly dates."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":115129},"source":{"system":"sec-edgar","filing":"0001803794-26-000002","document":"form4-07282026_040701.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1803794/000180379426000002/form4-07282026_040701.xml","form_type":"4"}},{"id":702024,"issuer":{"id":7139,"kind":"organization","name":"ImageneBio, Inc."},"owners":[{"id":22754,"kind":"person","name":"Yarema Kristin","position":1,"cik":"0001803794","reported_name":"Yarema Kristin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Restricted Stock Units","published_at":"2026-07-28T20:05:06.000Z","date":"2026-07-25","kind":"exercise","planned":false,"acquired":false,"shares":38376,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each RSU represents a contingent right to receive one share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSUs vest over four years, with 25% of the shares subject to RSUs vesting on the one-year anniversary of the vesting commencement date and the remaining 75% of the shares vesting in equal quarterly installments over the following 12 quarterly dates."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The RSUs vest over four years, with 25% of the shares subject to RSUs vesting on the one-year anniversary of the vesting commencement date and the remaining 75% of the shares vesting in equal quarterly installments over the following 12 quarterly dates."}],"balance_after":115129,"derivative":{"underlying":"Common Stock","underlying_shares":38376},"source":{"system":"sec-edgar","filing":"0001803794-26-000002","document":"form4-07282026_040701.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1803794/000180379426000002/form4-07282026_040701.xml","form_type":"4"}},{"id":702023,"issuer":{"id":7139,"kind":"organization","name":"ImageneBio, Inc."},"owners":[{"id":22754,"kind":"person","name":"Yarema Kristin","position":1,"cik":"0001803794","reported_name":"Yarema Kristin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-07-28T20:05:06.000Z","date":"2026-07-25","kind":"other","planned":false,"acquired":true,"shares":115129,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On July 28, 2025, the Reporting Person was granted restricted stock units (\"RSUs\"), which RSUs were previously reported in Table II. Effective with this filing, the Reporting Person has elected to report grants of RSUs that are settleable solely in shares of the Issuer's common stock in Table I as acquisitions of common stock, rather than in Table II as derivative securities. Previously reported unvested RSUs that had been reported in Table II are included in the amount of securities beneficially owned shown in Column 5 of Table I. The 115,129 unvested RSUs carried over from prior Table II reporting represent grant awarded on July 28, 2025 that vests on the schedule described in footnote 3. As reported in Column 9 of Table II, there are no remaining RSUs that settle in common stock."},{"field":"shares","element":"transactionShares","label":"F1","text":"On July 28, 2025, the Reporting Person was granted restricted stock units (\"RSUs\"), which RSUs were previously reported in Table II. Effective with this filing, the Reporting Person has elected to report grants of RSUs that are settleable solely in shares of the Issuer's common stock in Table I as acquisitions of common stock, rather than in Table II as derivative securities. Previously reported unvested RSUs that had been reported in Table II are included in the amount of securities beneficially owned shown in Column 5 of Table I. The 115,129 unvested RSUs carried over from prior Table II reporting represent grant awarded on July 28, 2025 that vests on the schedule described in footnote 3. As reported in Column 9 of Table II, there are no remaining RSUs that settle in common stock."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"On July 28, 2025, the Reporting Person was granted restricted stock units (\"RSUs\"), which RSUs were previously reported in Table II. Effective with this filing, the Reporting Person has elected to report grants of RSUs that are settleable solely in shares of the Issuer's common stock in Table I as acquisitions of common stock, rather than in Table II as derivative securities. Previously reported unvested RSUs that had been reported in Table II are included in the amount of securities beneficially owned shown in Column 5 of Table I. The 115,129 unvested RSUs carried over from prior Table II reporting represent grant awarded on July 28, 2025 that vests on the schedule described in footnote 3. As reported in Column 9 of Table II, there are no remaining RSUs that settle in common stock."}],"balance_after":238905,"source":{"system":"sec-edgar","filing":"0001803794-26-000002","document":"form4-07282026_040701.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1803794/000180379426000002/form4-07282026_040701.xml","form_type":"4"}},{"id":702022,"issuer":{"id":7139,"kind":"organization","name":"ImageneBio, Inc."},"owners":[{"id":22754,"kind":"person","name":"Yarema Kristin","position":1,"cik":"0001803794","reported_name":"Yarema Kristin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-07-28T20:05:06.000Z","date":"2026-07-25","kind":"exercise","planned":false,"acquired":true,"shares":38376,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":123776,"source":{"system":"sec-edgar","filing":"0001803794-26-000002","document":"form4-07282026_040701.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1803794/000180379426000002/form4-07282026_040701.xml","form_type":"4"}},{"id":834395,"issuer":{"id":7139,"kind":"organization","name":"ImageneBio, Inc."},"owners":[{"id":22754,"kind":"person","name":"Yarema Kristin","position":1,"cik":"0001803794","reported_name":"Yarema Kristin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-03-18T22:09:14.000Z","date":"2026-03-16","kind":"grant","planned":false,"acquired":true,"shares":128100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option vests over four years, with 25% of the shares subject to this option vesting on March 15, 2027, and the remaining shares vesting in 36 substantially equal monthly installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the 2025 Plan) through each such vesting date."}],"balance_after":128100,"derivative":{"exercise_price":6.2,"expiration_date":"2036-03-16","underlying":"Common Stock","underlying_shares":128100},"source":{"system":"sec-edgar","filing":"0001803794-26-000001","document":"form4-03182026_100308.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1803794/000180379426000001/form4-03182026_100308.xml","form_type":"4"}},{"id":834394,"issuer":{"id":7139,"kind":"organization","name":"ImageneBio, Inc."},"owners":[{"id":22754,"kind":"person","name":"Yarema Kristin","position":1,"cik":"0001803794","reported_name":"Yarema Kristin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-03-18T22:09:14.000Z","date":"2026-03-16","kind":"grant","planned":false,"acquired":true,"shares":85400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares of the Issuer's common stock (\"Common Stock\") underlying restricted stock units (\"RSUs\"). Each RSU represents the contingent right to receive one share of Common Stock upon settlement. 25% of RSUs will vest and settle into Common Stock on March 15, 2027, and the balance will vest in successive equal quarterly installments on each of the next 12 Standard Quarterly Dates thereafter, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2025 Equity Incentive Plan (the \"2025 Plan\")) through each such vesting date. The \"Standard Quarterly Dates\" are each of March 15, June 15, September 15 and December 15."}],"balance_after":85400,"source":{"system":"sec-edgar","filing":"0001803794-26-000001","document":"form4-03182026_100308.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1803794/000180379426000001/form4-03182026_100308.xml","form_type":"4"}},{"id":1078881,"issuer":{"id":7139,"kind":"organization","name":"ImageneBio, Inc."},"owners":[{"id":22754,"kind":"person","name":"Yarema Kristin","position":1,"cik":"0001803794","reported_name":"Yarema Kristin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Restricted Stock Units","published_at":"2025-07-31T01:30:44.000Z","date":"2025-07-28","kind":"grant","planned":false,"acquired":true,"shares":153505,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit (collectively, the \"RSUs\") represents a contingent right to receive one share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSUs vest over four years, with 25% of the shares subject to RSUs vesting on the one-year anniversary of the vesting commencement date and the remaining 75% of the shares vesting in equal quarterly installments over the following 12 quarterly dates."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The RSUs vest over four years, with 25% of the shares subject to RSUs vesting on the one-year anniversary of the vesting commencement date and the remaining 75% of the shares vesting in equal quarterly installments over the following 12 quarterly dates."}],"balance_after":153505,"derivative":{"underlying":"Common Stock","underlying_shares":153505},"source":{"system":"sec-edgar","filing":"0001415889-25-020660","document":"form4-07312025_010741.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1803794/000141588925020660/form4-07312025_010741.xml","form_type":"4"}},{"id":1078880,"issuer":{"id":7139,"kind":"organization","name":"ImageneBio, Inc."},"owners":[{"id":22754,"kind":"person","name":"Yarema Kristin","position":1,"cik":"0001803794","reported_name":"Yarema Kristin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2025-07-31T01:30:44.000Z","date":"2025-07-28","kind":"grant","planned":false,"acquired":true,"shares":460515,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests over four years, with 25% of the shares subject to this option vesting on July 25, 2026, and the remaining shares vesting in 36 substantially equal monthly installments thereafter."}],"balance_after":460515,"derivative":{"exercise_price":16.37,"expiration_date":"2035-07-27","underlying":"Common Stock","underlying_shares":460515},"source":{"system":"sec-edgar","filing":"0001415889-25-020660","document":"form4-07312025_010741.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1803794/000141588925020660/form4-07312025_010741.xml","form_type":"4"}},{"id":1306616,"issuer":{"id":84243,"kind":"organization","name":"Poseida Therapeutics, Inc.","symbol":"PSTX"},"owners":[{"id":22754,"kind":"person","name":"Yarema Kristin","position":1,"cik":"0001803794","reported_name":"Yarema Kristin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2025-01-08T14:07:35.000Z","date":"2025-01-08","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":345200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"As of immediately prior to and conditioned upon the effective time of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an \"Option\") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger and (b) one CVR in respect of each Share underlying such Option (the \"Option Consideration\"); provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount, but less than $13.00 (any such option, an \"Underwater Option\"), [continues to Footnote 5]"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"[Continues from Footnote 4] such Underwater Option was not entitled to any payment of the Cash Amount in respect thereof and each Underwater Option was converted into the right to receive the CVR included in the Option Consideration  with respect to each Share underlying such Underwater Option and became entitled to receive, at each time a milestone payment becomes due and payable under the terms of the CVR Agreement, an amount in cash equal to the product of (a) the total number of Shares underlying such Underwater Option, multiplied by (b) the amount, if any, by which (1) the Cash Amount plus the amount of such milestone payment plus the amount of any other milestone payments that previously became due and payable under the terms of the CVR Agreement exceeds (2) the exercise price per Share with respect to such Underwater Option plus the Milestone Payment Amounts (as such term is defined in the CVR Agreement), [continues to Footnote 6]"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"[Continues from Footnote 5] if any, previously paid pursuant to the CVR Agreement in respect of each CVR granted in respect of such Underwater Option; provided further, that any Option with an exercise price that was equal to or greater than $13.00, was cancelled immediately prior to the effective time of the Merger without any payment being made in respect thereof."}],"balance_after":0,"derivative":{"exercise_price":3.38,"expiration_date":"2034-01-01","underlying":"Common Stock","underlying_shares":345200},"source":{"system":"sec-edgar","filing":"0001415889-25-001080","document":"form4-01082025_070130.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1661460/000141588925001080/form4-01082025_070130.xml","form_type":"4"}},{"id":1306615,"issuer":{"id":84243,"kind":"organization","name":"Poseida Therapeutics, Inc.","symbol":"PSTX"},"owners":[{"id":22754,"kind":"person","name":"Yarema Kristin","position":1,"cik":"0001803794","reported_name":"Yarema Kristin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2025-01-08T14:07:35.000Z","date":"2025-01-08","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":498325,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"As of immediately prior to and conditioned upon the effective time of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an \"Option\") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger and (b) one CVR in respect of each Share underlying such Option (the \"Option Consideration\"); provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount, but less than $13.00 (any such option, an \"Underwater Option\"), [continues to Footnote 5]"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"[Continues from Footnote 4] such Underwater Option was not entitled to any payment of the Cash Amount in respect thereof and each Underwater Option was converted into the right to receive the CVR included in the Option Consideration  with respect to each Share underlying such Underwater Option and became entitled to receive, at each time a milestone payment becomes due and payable under the terms of the CVR Agreement, an amount in cash equal to the product of (a) the total number of Shares underlying such Underwater Option, multiplied by (b) the amount, if any, by which (1) the Cash Amount plus the amount of such milestone payment plus the amount of any other milestone payments that previously became due and payable under the terms of the CVR Agreement exceeds (2) the exercise price per Share with respect to such Underwater Option plus the Milestone Payment Amounts (as such term is defined in the CVR Agreement), [continues to Footnote 6]"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"[Continues from Footnote 5] if any, previously paid pursuant to the CVR Agreement in respect of each CVR granted in respect of such Underwater Option; provided further, that any Option with an exercise price that was equal to or greater than $13.00, was cancelled immediately prior to the effective time of the Merger without any payment being made in respect thereof."}],"balance_after":0,"derivative":{"exercise_price":2.62,"expiration_date":"2033-04-10","underlying":"Common Stock","underlying_shares":498325},"source":{"system":"sec-edgar","filing":"0001415889-25-001080","document":"form4-01082025_070130.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1661460/000141588925001080/form4-01082025_070130.xml","form_type":"4"}},{"id":1306614,"issuer":{"id":84243,"kind":"organization","name":"Poseida Therapeutics, Inc.","symbol":"PSTX"},"owners":[{"id":22754,"kind":"person","name":"Yarema Kristin","position":1,"cik":"0001803794","reported_name":"Yarema Kristin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-01-08T14:07:35.000Z","date":"2025-01-08","kind":"other","planned":false,"acquired":false,"shares":615836,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Disposed of pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of November 25, 2024, by and among Poseida Therapeutics, Inc. (the \"Issuer\"), Roche Holdings, Inc. (\"Parent\") and Blue Giant Acquisition Corp., a wholly owned subsidiary of Parent (\"Merger Sub\").  On January 8, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a \"Share\") for an offer price of (i) $9.00 per Share in cash (the \"Cash Amount\"), and (ii) one non-tradeable contingent value right (each, a \"CVR\") representing the right to receive certain contingent payments of up to an aggregate amount of $4.00 per Share, [continues to Footnote 2]"},{"field":"shares","element":"transactionShares","label":"F2","text":"[continues from Footnote 1] in cash, upon the achievement of specified milestones, subject to and in accordance with the terms of the Contingent Value Rights Agreement (the \"CVR Agreement\"), in each case, without interest, and subject to any applicable withholding taxes (the Cash Amount plus one CVR, collectively, the \"Offer Price\").  Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the \"Merger\"). At the effective time of the Merger, each issued and outstanding Share (other than any Excluded Shares (as such term is defined in the Merger Agreement)) was cancelled in exchange for the right to receive the Offer Price."},{"field":"shares","element":"transactionShares","label":"F3","text":"Includes 3,000 shares acquired by the Reporting Person under the Issuer's 2020 Employee Stock Purchase Plan (the \"ESPP\") on March 20, 2024, 3,000 shares acquired by the Reporting Person under the ESPP on September 20, 2024 and 3,000 shares acquired by the Reporting Person under the ESPP on January 2, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Disposed of pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of November 25, 2024, by and among Poseida Therapeutics, Inc. (the \"Issuer\"), Roche Holdings, Inc. (\"Parent\") and Blue Giant Acquisition Corp., a wholly owned subsidiary of Parent (\"Merger Sub\").  On January 8, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a \"Share\") for an offer price of (i) $9.00 per Share in cash (the \"Cash Amount\"), and (ii) one non-tradeable contingent value right (each, a \"CVR\") representing the right to receive certain contingent payments of up to an aggregate amount of $4.00 per Share, [continues to Footnote 2]"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"[continues from Footnote 1] in cash, upon the achievement of specified milestones, subject to and in accordance with the terms of the Contingent Value Rights Agreement (the \"CVR Agreement\"), in each case, without interest, and subject to any applicable withholding taxes (the Cash Amount plus one CVR, collectively, the \"Offer Price\").  Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the \"Merger\"). At the effective time of the Merger, each issued and outstanding Share (other than any Excluded Shares (as such term is defined in the Merger Agreement)) was cancelled in exchange for the right to receive the Offer Price."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001415889-25-001080","document":"form4-01082025_070130.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1661460/000141588925001080/form4-01082025_070130.xml","form_type":"4"}},{"id":1687801,"issuer":{"id":84243,"kind":"organization","name":"Poseida Therapeutics, Inc.","symbol":"PSTX"},"owners":[{"id":22754,"kind":"person","name":"Yarema Kristin","position":1,"cik":"0001803794","reported_name":"Yarema Kristin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to buy)","published_at":"2024-01-04T16:03:48.000Z","date":"2024-01-02","kind":"grant","planned":false,"acquired":true,"shares":345200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"12.5% of the shares subject to the stock option will vest and become exercisable on the six-month anniversary of January 1, 2024, and the remaining shares will vest in 42 equal monthly installments thereafter."}],"balance_after":345200,"derivative":{"exercise_price":3.38,"expiration_date":"2034-01-01","underlying":"Common Stock","underlying_shares":345200},"source":{"system":"sec-edgar","filing":"0000950170-24-001835","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1661460/000095017024001835/ownership.xml","form_type":"4"}},{"id":1687800,"issuer":{"id":84243,"kind":"organization","name":"Poseida Therapeutics, Inc.","symbol":"PSTX"},"owners":[{"id":22754,"kind":"person","name":"Yarema Kristin","position":1,"cik":"0001803794","reported_name":"Yarema Kristin","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-01-04T16:03:48.000Z","date":"2024-01-02","kind":"grant","planned":false,"acquired":true,"shares":250000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares issuable upon the vesting of restricted stock units granted pursuant to the Issuer's Equity Incentive Plan. The RSUs are scheduled to vest in four equal annual installments beginning from the first anniversary of January 1, 2024."}],"balance_after":606836,"source":{"system":"sec-edgar","filing":"0000950170-24-001835","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1661460/000095017024001835/ownership.xml","form_type":"4"}},{"id":1920962,"issuer":{"id":84243,"kind":"organization","name":"Poseida Therapeutics, Inc.","symbol":"PSTX"},"owners":[{"id":22754,"kind":"person","name":"Yarema Kristin","position":1,"cik":"0001803794","reported_name":"Yarema Kristin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Cell Therapy"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2023-04-12T16:49:54.000Z","date":"2023-04-11","kind":"grant","planned":false,"acquired":true,"shares":498325,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"12.5% of the shares subject to the stock option will vest and become exercisable on the six-month anniversary of the grant date listed in column 3 above, and the remaining shares will vest in 42 equal monthly installments thereafter."}],"balance_after":498325,"derivative":{"exercise_price":2.62,"expiration_date":"2033-04-10","underlying":"Common Stock","underlying_shares":498325},"source":{"system":"sec-edgar","filing":"0001209191-23-024103","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1661460/000120919123024103/doc4.xml","form_type":"4"}},{"id":1920961,"issuer":{"id":84243,"kind":"organization","name":"Poseida Therapeutics, Inc.","symbol":"PSTX"},"owners":[{"id":22754,"kind":"person","name":"Yarema Kristin","position":1,"cik":"0001803794","reported_name":"Yarema Kristin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Cell Therapy"}}],"security":"Common Stock","published_at":"2023-04-12T16:49:54.000Z","date":"2023-04-11","kind":"grant","planned":false,"acquired":true,"shares":356836,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares issuable upon the vesting of restricted stock units granted pursuant to the Issuer's 2022 Inducement Plan. The RSUs are scheduled to vest in four equal annual installments."}],"balance_after":356836,"source":{"system":"sec-edgar","filing":"0001209191-23-024103","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1661460/000120919123024103/doc4.xml","form_type":"4"}},{"id":2352701,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":22754,"kind":"person","name":"Yarema Kristin","position":1,"cik":"0001803794","reported_name":"Yarema Kristin","relationship":{"officer":true,"officer_title":"Chief Commercial Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2022-03-04T00:02:35.000Z","date":"2022-03-01","kind":"grant","acquired":true,"shares":85592,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"1/48th of the shares subject to the stock option vest and become exercisable each month with the initial installment vesting on April 1, 2022, subject to the reporting person's continuous service."}],"balance_after":85592,"derivative":{"exercise_price":10.21,"expiration_date":"2032-02-28","underlying":"Common Stock","underlying_shares":85592},"source":{"system":"sec-edgar","filing":"0001140361-22-007766","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1604464/000114036122007766/form4.xml","form_type":"4"}},{"id":2352700,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":22754,"kind":"person","name":"Yarema Kristin","position":1,"cik":"0001803794","reported_name":"Yarema Kristin","relationship":{"officer":true,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2022-03-04T00:02:35.000Z","date":"2022-03-01","kind":"grant","acquired":true,"shares":45533,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These restricted stock units vest in 16 equal quarterly installments on each Company Quarterly Vesting Date (as defined below), with the initial installment vesting on May 15, 2022, subject to the reporting person's continuous service. Company Quarterly Vesting Date means March 1, May 15, August 15 and November 15 of each year."}],"balance_after":171415,"source":{"system":"sec-edgar","filing":"0001140361-22-007766","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1604464/000114036122007766/form4.xml","form_type":"4"}},{"id":2667585,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":22754,"kind":"person","name":"Yarema Kristin","position":1,"cik":"0001803794","reported_name":"Yarema Kristin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2021-06-15T20:02:31.000Z","date":"2021-06-14","kind":"purchase","acquired":true,"shares":28833,"price":14.58,"value":420385.14,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reporting person's sale of ATRA common stock reported herein was matchable under Section 16(b) of the Securities Exchange Act of 1934, to the extent of 761 shares, with the reporting person's sale of 761 shares of ATRA common stock at a weighted average price of $14.55 per share on May 18, 2021. The reporting person has agreed to pay to ATRA $53.27, representing the full amount of the profit realized in connection with the short-swing transaction."}],"balance_after":125882,"source":{"system":"sec-edgar","filing":"0001567619-21-012110","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1604464/000156761921012110/doc1.xml","form_type":"4"}},{"id":2667584,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":22754,"kind":"person","name":"Yarema Kristin","position":1,"cik":"0001803794","reported_name":"Yarema Kristin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2021-06-15T20:02:31.000Z","date":"2021-06-14","kind":"purchase","acquired":true,"shares":3500,"price":14.48,"value":50680.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reporting person's sale of ATRA common stock reported herein was matchable under Section 16(b) of the Securities Exchange Act of 1934, to the extent of 761 shares, with the reporting person's sale of 761 shares of ATRA common stock at a weighted average price of $14.55 per share on May 18, 2021. The reporting person has agreed to pay to ATRA $53.27, representing the full amount of the profit realized in connection with the short-swing transaction."}],"balance_after":97049,"source":{"system":"sec-edgar","filing":"0001567619-21-012110","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1604464/000156761921012110/doc1.xml","form_type":"4"}},{"id":2667583,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":22754,"kind":"person","name":"Yarema Kristin","position":1,"cik":"0001803794","reported_name":"Yarema Kristin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2021-06-15T20:02:31.000Z","date":"2021-06-11","kind":"purchase","acquired":true,"shares":2021,"price":14.5,"value":29304.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reporting person's sale of ATRA common stock reported herein was matchable under Section 16(b) of the Securities Exchange Act of 1934, to the extent of 761 shares, with the reporting person's sale of 761 shares of ATRA common stock at a weighted average price of $14.55 per share on May 18, 2021. The reporting person has agreed to pay to ATRA $53.27, representing the full amount of the profit realized in connection with the short-swing transaction."}],"balance_after":93549,"source":{"system":"sec-edgar","filing":"0001567619-21-012110","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1604464/000156761921012110/doc1.xml","form_type":"4"}},{"id":2702483,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":22754,"kind":"person","name":"Yarema Kristin","position":1,"cik":"0001803794","reported_name":"Yarema Kristin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2021-05-20T20:29:16.000Z","date":"2021-05-18","kind":"sale","acquired":false,"shares":761,"price":14.55,"value":11072.55,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold pursuant to a 10b5-1 arrangement to satisfy tax obligations in connection with the vesting of previously granted Restricted Stock Units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on May 18, 2021 and May 19, 2021 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employees."}],"balance_after":91528,"source":{"system":"sec-edgar","filing":"0001209191-21-034422","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1604464/000120919121034422/doc4.xml","form_type":"4"}},{"id":2811299,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":22754,"kind":"person","name":"Yarema Kristin","position":1,"cik":"0001803794","reported_name":"Yarema Kristin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2021-03-03T22:15:19.000Z","date":"2021-03-01","kind":"grant","acquired":true,"shares":52862,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"1/48th of the shares subject to the stock option vest and become exercisable each month with the initial installment vesting on April 1, 2021, subject to the reporting person's continuous service."}],"balance_after":52862,"derivative":{"exercise_price":17.105,"expiration_date":"2031-02-28","underlying":"Common Stock","underlying_shares":52862},"source":{"system":"sec-edgar","filing":"0001209191-21-017037","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1604464/000120919121017037/doc4.xml","form_type":"4"}},{"id":2811298,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":22754,"kind":"person","name":"Yarema Kristin","position":1,"cik":"0001803794","reported_name":"Yarema Kristin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2021-03-03T22:15:19.000Z","date":"2021-03-01","kind":"grant","acquired":true,"shares":35021,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These restricted stock units vest in 16 equal quarterly installments on each Company Quarterly Vesting Date (as defined below), with the initial installment vesting on May 15, 2021, subject to the reporting person's continuous service.  Company Quarterly Vesting Date means March 1, May 15, August 15 and November 15 of each year."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 2,268 shares purchased pursuant to the Issuer's Employee Stock Purchase Plan on November 30, 2020."}],"balance_after":92289,"source":{"system":"sec-edgar","filing":"0001209191-21-017037","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1604464/000120919121017037/doc4.xml","form_type":"4"}},{"id":3230640,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":22754,"kind":"person","name":"Yarema Kristin","position":1,"cik":"0001803794","reported_name":"Yarema Kristin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2020-03-03T22:00:50.000Z","date":"2020-03-01","kind":"grant","acquired":true,"shares":55000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These restricted stock units vest as to 25% of the shares on March 1, 2021 and the remaining shares vest in 12 equal quarterly installments on each Company Quarterly Vesting Date (as defined below) following March 1, 2021, subject to the reporting person's continuous service.  Company Quarterly Vesting Date means March 1, May 15, August 15 and November 15 of each year."}],"balance_after":55000,"source":{"system":"sec-edgar","filing":"0001209191-20-015360","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1604464/000120919120015360/doc4.xml","form_type":"4"}},{"id":3261918,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":22754,"kind":"person","name":"Yarema Kristin","position":1,"cik":"0001803794","reported_name":"Yarema Kristin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2020-02-20T01:53:53.000Z","date":"2020-02-18","kind":"grant","acquired":true,"shares":110000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to the option vest on February 18, 2021 and the remaining shares vest in equal monthly installments over the following 36 months."}],"balance_after":110000,"derivative":{"exercise_price":14.56,"expiration_date":"2030-02-17","underlying":"Common Stock","underlying_shares":110000},"source":{"system":"sec-edgar","filing":"0001209191-20-010848","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1604464/000120919120010848/doc4.xml","form_type":"4"}}]}